APO-ALENDRONATE/VITAMIN D3 TABLET

দেশ: কানাডা

ভাষা: ইংরেজি

সূত্র: Health Canada

সক্রিয় উপাদান:

ALENDRONIC ACID (ALENDRONATE SODIUM); VITAMIN D3 (CHOLECALCIFEROL)

থেকে পাওয়া:

APOTEX INC

এটিসি কোড:

M05BB03

INN (আন্তর্জাতিক নাম):

ALENDRONIC ACID AND CHOLECALCIFEROL

ডোজ:

70MG; 5600UNIT

ফার্মাসিউটিকাল ফর্ম:

TABLET

রচনা:

ALENDRONIC ACID (ALENDRONATE SODIUM) 70MG; VITAMIN D3 (CHOLECALCIFEROL) 5600UNIT

প্রশাসন রুট:

ORAL

প্যাকেজ ইউনিট:

4

প্রেসক্রিপশন টাইপ:

Prescription

থেরাপিউটিক এলাকা:

VITAMIN D

পণ্য সারাংশ:

Active ingredient group (AIG) number: 0251575002; AHFS:

অনুমোদন অবস্থা:

APPROVED

অনুমোদন তারিখ:

2016-05-03

পণ্য বৈশিষ্ট্য

PRODUCT MONOGRAPH
PR
APO-ALENDRONATE / VITAMIN D
3
alendronate sodium/cholecalciferol tablets
70 MG ALENDRONATE + 70 MCG CHOLECALCIFEROL (2800 IU VITAMIN D
3
)
and
70 MG ALENDRONATE + 140 MCG CHOLECALCIFEROL (5600 IU VITAMIN D
3
)
Bone Metabolism Regulator and Vitamin D
APOTEX INC. DATE OF REVISION:
150 SIGNET DRIVE OCTOBER 3, 2017
TORONTO, ONTARIO
M9L 1T9
SUBMISSION CONTROL NO: 209085
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.............................................................................
3
SUMMARY PRODUCT INFORMATION
...................................................................................................
3
INDICATIONS AND CLINICAL USE
........................................................................................................
3
CONTRAINDICATIONS
..............................................................................................................................
4
WARNINGS AND PRECAUTIONS
............................................................................................................
4
ADVERSE REACTIONS
..............................................................................................................................
8
DRUG INTERACTIONS
.............................................................................................................................14
DOSAGE AND ADMINISTRATION
.........................................................................................................15
OVERDOSAGE
...........................................................................................................................................16
ACTION AND CLINICAL PHARMACOLOGY
.......................................................................................17
STORAGE AND STABILITY
....................................................................................................................22
DOSAGE FORMS, COMPOSITION AND PACKAGING
........................................................................22
PART II: SCIE